Associations between reduced AGR2 expression and unfavorable tumor features have been described for colorectal cancer [39], ductal adenocarcinoma of the pancreas [40], prostate cancer [41], ovarian cancer [16, 25], and adenocarcinoma of the lung [42] although other groups could not confirm these findings for ovarian [31] and lung cancer [28] and others even found a link between low AGR expression and favorable tumor features for lung [10], ovarian, [31] and prostate cancer [23]. This evidence concerns the gene AGR2 and pancreatic ductal adenocarcinoma.